Phibro Animal Health (PAHC) Downgraded to “Strong Sell” at BidaskClub

Phibro Animal Health (NASDAQ:PAHC) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued to clients and investors on Thursday.

A number of other research analysts have also recently commented on PAHC. Zacks Investment Research cut Phibro Animal Health from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 24th. ValuEngine cut Phibro Animal Health from a “buy” rating to a “hold” rating in a research note on Monday, November 12th. Four investment analysts have rated the stock with a sell rating and two have given a hold rating to the company’s stock. The stock presently has an average rating of “Sell” and an average target price of $43.50.

PAHC opened at $28.80 on Thursday. The company has a market capitalization of $1.18 billion, a PE ratio of 16.55, a PEG ratio of 3.07 and a beta of 0.63. The company has a debt-to-equity ratio of 1.52, a current ratio of 3.25 and a quick ratio of 1.83. Phibro Animal Health has a 52 week low of $28.78 and a 52 week high of $54.62.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, February 6th. The company reported $0.41 EPS for the quarter, missing the Zacks’ consensus estimate of $0.43 by ($0.02). The firm had revenue of $218.20 million during the quarter, compared to analysts’ expectations of $211.59 million. Phibro Animal Health had a net margin of 8.69% and a return on equity of 36.37%. The company’s revenue for the quarter was up 6.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.44 EPS. As a group, research analysts expect that Phibro Animal Health will post 1.7 earnings per share for the current fiscal year.

In other Phibro Animal Health news, VP Daniel M. Bendheim sold 5,000 shares of Phibro Animal Health stock in a transaction on Wednesday, January 9th. The stock was sold at an average price of $32.43, for a total transaction of $162,150.00. Following the completion of the transaction, the vice president now owns 2,500 shares in the company, valued at $81,075. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Daniel M. Bendheim sold 2,500 shares of Phibro Animal Health stock in a transaction on Monday, January 28th. The shares were sold at an average price of $31.55, for a total value of $78,875.00. Following the transaction, the vice president now owns 2,500 shares of the company’s stock, valued at approximately $78,875. The disclosure for this sale can be found here. In the last 90 days, insiders sold 51,450 shares of company stock valued at $1,641,797. 50.29% of the stock is currently owned by company insiders.

Several hedge funds have recently bought and sold shares of the company. Victory Capital Management Inc. lifted its position in shares of Phibro Animal Health by 4.1% in the fourth quarter. Victory Capital Management Inc. now owns 10,756 shares of the company’s stock valued at $346,000 after acquiring an additional 419 shares in the last quarter. Algert Global LLC lifted its position in shares of Phibro Animal Health by 1.6% in the fourth quarter. Algert Global LLC now owns 28,849 shares of the company’s stock valued at $928,000 after acquiring an additional 464 shares in the last quarter. Texas Permanent School Fund lifted its position in shares of Phibro Animal Health by 4.5% in the fourth quarter. Texas Permanent School Fund now owns 13,225 shares of the company’s stock worth $425,000 after buying an additional 564 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Phibro Animal Health by 52.3% in the fourth quarter. Advisors Asset Management Inc. now owns 2,536 shares of the company’s stock worth $82,000 after buying an additional 871 shares in the last quarter. Finally, Campbell & CO Investment Adviser LLC lifted its position in shares of Phibro Animal Health by 17.6% in the fourth quarter. Campbell & CO Investment Adviser LLC now owns 8,205 shares of the company’s stock worth $292,000 after buying an additional 1,225 shares in the last quarter. Hedge funds and other institutional investors own 50.38% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as a diversified animal health and mineral nutrition company primarily in the United States. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets products for a range of food animals, including poultry, swine, beef and dairy cattle, and aquaculture.

Featured Article: Price to Earnings Ratio (PE)

Receive News & Ratings for Phibro Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phibro Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply